Qi Zhang, Guozhen Liu, Li Jing, Sis Aghayants, Fangjing Xu, Yucheng Fan
Skin diseases encompass a diverse range of conditions with significant psychological and physiological impacts. N6-methyladenosine (m6A) RNA methylation is a key epitranscriptomic modification that regulates gene expression by influencing RNA stability, splicing, translation, export, and degradation. Recent studies have highlighted the crucial role of m6A modification in the pathogenesis and progression of various skin diseases. M6A modification affects critical biological processes of the skin, such as inflammation, immune response, and cellular aging. This review systematically explores the landscape of m6A modification in non-tumor skin diseases, elucidating its regulatory roles and therapeutic implications, including wound healing, scar and keloid, skin aging, psoriasis, systemic lupus erythematosus, acne vulgaris, rosacea, chronic actinic dermatitis, and scleroderma. The intricate mechanisms of m6A modification can lead to the development of novel diagnostic biomarkers and therapeutic strategies, ultimately improving patient outcomes.
{"title":"The Landscape of m6A RNA Methylation in Skin Diseases.","authors":"Qi Zhang, Guozhen Liu, Li Jing, Sis Aghayants, Fangjing Xu, Yucheng Fan","doi":"10.1093/bjd/ljaf087","DOIUrl":"https://doi.org/10.1093/bjd/ljaf087","url":null,"abstract":"<p><p>Skin diseases encompass a diverse range of conditions with significant psychological and physiological impacts. N6-methyladenosine (m6A) RNA methylation is a key epitranscriptomic modification that regulates gene expression by influencing RNA stability, splicing, translation, export, and degradation. Recent studies have highlighted the crucial role of m6A modification in the pathogenesis and progression of various skin diseases. M6A modification affects critical biological processes of the skin, such as inflammation, immune response, and cellular aging. This review systematically explores the landscape of m6A modification in non-tumor skin diseases, elucidating its regulatory roles and therapeutic implications, including wound healing, scar and keloid, skin aging, psoriasis, systemic lupus erythematosus, acne vulgaris, rosacea, chronic actinic dermatitis, and scleroderma. The intricate mechanisms of m6A modification can lead to the development of novel diagnostic biomarkers and therapeutic strategies, ultimately improving patient outcomes.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuan-Liang Wen, Wan-Ting Hsu, Yi-Hsien Chen, Hui-Han Kao, Chun-Cheng Liao, Sheng-Yin To, Hui-Wen Yang, Li-Ting Kao
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a novel class of antidiabetic medications, have emerged as a key treatment option for diabetes management. Notably, SGLT2i promote glucose and sodium excretion through urine, a mechanism that may be implicated in the potential association between SGLT2i use and atopic dermatitis (AD) risk.
Objectives: This study investigated the relationship between SGLT2i use and new-onset AD in diabetic patients.
Methods: This nationwide active-comparator cohort study utilized data from the Taiwan National Health Insurance Database to investigate the association between SGLT2i use and AD risk. The study included adult patients with type 2 diabetes who initiated SGLT2i or DPP4i between May 2016 and December 2018, with no prescriptions for other SGLT2i or DPP4i in the 12 months prior to cohort entry. A total of 148,354 SGLT2i users were identified as the study group, while 322,703 DPP4i users were designated as the active comparator group. The primary outcome was the incidence of AD. To minimize potential confounding, inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics, medical history, and ever having medication use between the two groups. Additionally, sensitivity analyses, subgroup analyses, and gender-specific assessments were conducted to further validate the findings. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of developing AD.
Results: In the full cohort, SGLT2i users had a lower AD incidence (9.742 vs. 12.070 per 1,000 person-years) than DPP4i users. SGLT2i users had a significantly lower risk of AD compared to DPP4i users (HR = 0.847) after IPTW adjustment. Different SGLT2i types also showed a consistent protective effect for AD. Notably, the highest SGLT2i dosage was associated with the lowest AD risk (IPTW-adjusted HR = 0.647), consistent across sensitivity analyses. Additionally, male SGLT2i users exhibit a much lower risk of AD (IPTW-adjusted HR=0.750) than female SGLT2i users.
Conclusions: SGLT2i show a significant protective effect against AD in diabetic patients compared to DPP4i. This robust finding, consistent across weighting and sensitivity analyses, supports SGLT2i use, with a strong protective effect also observed in the dose-response analysis.
{"title":"Sodium-glucose Cotransporter 2 Inhibitors and Inverse Risk of New-onset Atopic Dermatitis in Diabetic Population: a Nationwide, Active-comparator Study.","authors":"Yuan-Liang Wen, Wan-Ting Hsu, Yi-Hsien Chen, Hui-Han Kao, Chun-Cheng Liao, Sheng-Yin To, Hui-Wen Yang, Li-Ting Kao","doi":"10.1093/bjd/ljaf086","DOIUrl":"https://doi.org/10.1093/bjd/ljaf086","url":null,"abstract":"<p><strong>Background: </strong>Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a novel class of antidiabetic medications, have emerged as a key treatment option for diabetes management. Notably, SGLT2i promote glucose and sodium excretion through urine, a mechanism that may be implicated in the potential association between SGLT2i use and atopic dermatitis (AD) risk.</p><p><strong>Objectives: </strong>This study investigated the relationship between SGLT2i use and new-onset AD in diabetic patients.</p><p><strong>Methods: </strong>This nationwide active-comparator cohort study utilized data from the Taiwan National Health Insurance Database to investigate the association between SGLT2i use and AD risk. The study included adult patients with type 2 diabetes who initiated SGLT2i or DPP4i between May 2016 and December 2018, with no prescriptions for other SGLT2i or DPP4i in the 12 months prior to cohort entry. A total of 148,354 SGLT2i users were identified as the study group, while 322,703 DPP4i users were designated as the active comparator group. The primary outcome was the incidence of AD. To minimize potential confounding, inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics, medical history, and ever having medication use between the two groups. Additionally, sensitivity analyses, subgroup analyses, and gender-specific assessments were conducted to further validate the findings. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of developing AD.</p><p><strong>Results: </strong>In the full cohort, SGLT2i users had a lower AD incidence (9.742 vs. 12.070 per 1,000 person-years) than DPP4i users. SGLT2i users had a significantly lower risk of AD compared to DPP4i users (HR = 0.847) after IPTW adjustment. Different SGLT2i types also showed a consistent protective effect for AD. Notably, the highest SGLT2i dosage was associated with the lowest AD risk (IPTW-adjusted HR = 0.647), consistent across sensitivity analyses. Additionally, male SGLT2i users exhibit a much lower risk of AD (IPTW-adjusted HR=0.750) than female SGLT2i users.</p><p><strong>Conclusions: </strong>SGLT2i show a significant protective effect against AD in diabetic patients compared to DPP4i. This robust finding, consistent across weighting and sensitivity analyses, supports SGLT2i use, with a strong protective effect also observed in the dose-response analysis.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Anatomical distribution of acral lentiginous melanoma in the hand and nail among Japanese individuals.","authors":"Yuna Kochi, Yaei Togawa, Yuriko Yamazaki, Yosuke Yamamoto, Keisuke Suehiro, Hiroyuki Matsue, Takashi Inozume","doi":"10.1093/bjd/ljaf070","DOIUrl":"https://doi.org/10.1093/bjd/ljaf070","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on 'Incidence of non-infectious uveitis among patients with hidradenitis suppurativa': reply from authors.","authors":"Andrew Strunk, Amit Garg","doi":"10.1093/bjd/ljaf084","DOIUrl":"https://doi.org/10.1093/bjd/ljaf084","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Haematological cancers and skin cancer: statistics from the Netherlands.","authors":"Lena A von Schuckmann, Kiarash Khosrotehrani","doi":"10.1093/bjd/ljaf081","DOIUrl":"https://doi.org/10.1093/bjd/ljaf081","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alan Y Hsu, Chun-Ju Lin, Ning-Yi Hsia, Chun-Ting Lai, Yi-Yu Tsai
{"title":"Comment on 'Incidence of non-infectious uveitis among patients with hidradenitis suppurativa'.","authors":"Alan Y Hsu, Chun-Ju Lin, Ning-Yi Hsia, Chun-Ting Lai, Yi-Yu Tsai","doi":"10.1093/bjd/ljaf083","DOIUrl":"https://doi.org/10.1093/bjd/ljaf083","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ipilimumab + nivolumab combination or nivolumab monotherapy as first-line treatment in patients with metastatic melanoma: conclusions from a real-world French national cohort.","authors":"Charlée Nardin, Dewi Vernerey, François Aubin","doi":"10.1093/bjd/ljaf080","DOIUrl":"https://doi.org/10.1093/bjd/ljaf080","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Setting the melanoma research agenda for all end-users: the need to include patient, clinician, and policy perspectives.","authors":"Deonna M Ackermann, Katy J L Bell","doi":"10.1093/bjd/ljaf082","DOIUrl":"https://doi.org/10.1093/bjd/ljaf082","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"First-line treatment patterns and overall survival in patients diagnosed with metastatic Merkel cell carcinoma in England from 2013 to 2020: results of a nationwide observational cohort study.","authors":"Seyed Hamidreza Mahmoudpour, Craig Knott, Jenny Nobes, Mairead Kearney, Emmanuelle Boutmy, Patrice Verpillat, Zoe C Venables","doi":"10.1093/bjd/ljaf063","DOIUrl":"https://doi.org/10.1093/bjd/ljaf063","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号